Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
East Rutherford, NJ – January 18, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
“Today, we welcome our new colleagues from Snapdragon to Cambrex,” said Tom Loewald, CEO of Cambrex. “With Snapdragon’s depth of scientific expertise in API process development, I’m certain our customers will see the benefits of this combination and be delighted to work with Snapdragon’s team.”
“I am extremely proud of what our team at Snapdragon has built over the years,” said Matt Bio, CEO of Snapdragon. “With Cambrex, we have found an ideal home for our customers and employees, and I look forward to continued success as part of Cambrex.”
Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.
Cambrex continues to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing, with Snapdragon bolstering its depth of expertise in continuous flow manufacturing and complementing recent investments in continuous flow process development capabilities at its High Point, North Carolina facility.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With over 40 years of experience and a growing team of over 2,300 experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing. Cambrex offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/d6d18ff8-39d3-4047-b805-cff46eed1dc6.png?optimizer=image&width=360&aspect_ratio=3:4)
bit.bio chooses Automata for automating an aspect of its production of iPSC derived human cells
26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell)-derived human cell products.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/2a446651-4aa1-454e-8fe7-b0f1714fecd5.png?optimizer=image&width=360&aspect_ratio=3:4)
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/7ce8f780-11bc-451e-b11e-aa0b6d632178.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher and AstraZeneca partner to Develop Solid Tissue, Blood-Based Companion Diagnostic Test
24 January -- CARLSBAD, Calif.--(BUSINESS WIRE)-- As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/1b83c600-5a94-4609-a117-c3cc2e65f43d.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/b7b6cdbd-5c4c-4ea3-999d-354c99ff80f1.png?optimizer=image&width=360&aspect_ratio=3:4)
rms Company Scales Medical Device Production with Addition of 3D Systems’ DMP Flex 350 Dual
ROCK HILL, South Carolina, January 19, 2023 – Today, 3D Systems (NYSE:DDD) announced rms Company, one of the largest contract manufacturers of high-quality, tight-tolerance medical devices in the world, has added the DMP Flex 350 Dual to its production workflow. rms has more than 30 3D Systems’ DMP 3D printers in its additive manufacturing facility enabling the company to provide a complete Powder to Package capability to medical device OEMs.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
